Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 26110

· U.S. Patent Application No. 11/044,224 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (Continuation application of Patent No. 6,846,605).

· Provisional Patent Application No. 60/742,191 Alpha-1-antitrypsin inhibition of disease and conditions mediated by binding to cell-associate actin (related to Case # CU1428H).

· Provisional Application No. 60/913,174 Title Compositions and Methods of Use for Alpha­Anti Trypsin Having No Significant Serine Protease Inhibitor Activity (CU1697H US).

· PCT Application No, PCT/US2006/061577 Title Compositions and Methods For Treating Actin-Mediated Conditions (CU1428H).

· U.S. Patent Application No.11/719,200 Compositions and Methods For Treating Actin- Mediated Conditions (CU1428H US1).

Treatment of all viral infections including, without limitation, any and all mutations, strains, and subtypes, including future mutations, strains, and subtypes of Human Immunodeficiency Virus (HIV) (including any viral infections reasonably and/or previously withheld by the University, when they become available); Human Papilloma Virus (HPV); Herpes Simplex Virus (HSV); Hepacivirus; Pestivirus; Avian influenza virus; Human influenza virus; Murray Valley encephalitis; St. Louis encephalitis.

Product relates to brand name Fuzeon® in indications other than the treatment of HIV.  Fuzeon was developed in collaboration with the Licensee, and is our only currently marketed product.  Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.  The FDA approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.

Date U.S. Pat. No. 5,464,933 11/7/95 Synthetic Peptide Inhibitors of HIV Transmission 6/7/2013
U.S. Patent No. 6,133,418 10/17/00 Synthetic Peptide Inhibitors of HIV Transmission 11/17/2014
U.S. Patent No. 6,475,491 11/5/02 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/7/2015
U.S. Patent No. 6,861,059 3/1/05 Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations 9/9/2015
Canadian Patent No. 2,224,008 8/18/09 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/6/2016
U.S. Patent No. 6,281,331 8/28/01 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,015,881 1/18/00 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,824,783 11/30/04 Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission 11/30/2021

The University grants a Co-Exclusive license and a Tri-Exclusive license under the Licensed Patents to manufacture, have manufactured on Companys behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory.

Tri-Exclusive means, with respect to a license, that such license may only be granted to Company and two Third Parties.

Genital herpes is a sexually transmitted disease caused by the herpes simplex viruses HSV-1 or HSV-2, and in extreme cases, can appear in and about the eyes, esophagus, trachea, brain, and arms and legs.

Neuraminidase inhibitors work against influenza by preventing viruses from being released from infected cells and subsequently infecting further cells. Neuraminidase inhibitors are usually prescribed to patients presenting with flu-like symptoms during epidemic periods to reduce symptoms or prevent spread of the virus.

The licensed patents include
— Antibodies and Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Viral Inhibition & Disease Treatment,
— Methods For Treating Viral Infections Using Antibodies To Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Antibodies to Aminophospholipids,
— Methods for Treating Viral Infections Using Immunoconjugates to Aminophospholipids,
— Compositions for Treating Viral Infections Using lmmunoconjugates to Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Immunoconjugates To Aminophospholipids,
— Selected Antibodies and Duramycin Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Treating Viral Infections and Cancer,
— Selected Antibody Compositions For Binding To Aminophospholipids,
— Selected Antibody Compositions and Methods For Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Combined Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Selected Antibody CDRs for Binding To Aminophospholipids,
— Liposomes Coated with Selected Antibodies That Bind to Aminophospholipids,
— Combinations and Kits For Cancer Treatment Using Selected Antibodies to Aminophospholipids,
— Selected Immunoconjugates for Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Immunoconjugates For Binding To Aminophospholipids,
— Selected Antibodies & Duramycin Peptides Binding to Anionic Phospholipids & Aminophospholipids &
Their Use in Treating Viral Infections & Cancer,
— Compositions Comprising Cell-Impermeant Duramycin Derivatives,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptide Derivatives,
— Compositions Comprising Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents, and,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents.